B cell lymphomas are a heterogeneous group of malignancies affecting B lymphocytes that
play an essential role in immune responses as they differentiate into antibodysecreting …

The two histone deacetylases (Hdacs), Hdac1 and Hdac2, are erasers of acetylation marks
on histone tails, and are important regulators of gene expression that were shown to play …

Background Diffuse large B cell lymphomas (DLBCL) are aggressive tumours with frequent
aberrations in epigenetic proteins. Histone deacetylase inhibitors (HDACi) are epigenetic …

In this study, we reviewed epigenetic therapy of lymphomas using histone deacetylase
inhibitors (HDACi), a promising new class of antineoplastic agents. Epigenetic therapy, a …

T-cell lymphomas are a heterogeneous group of cancers with different pathogenesis and
poor prognosis. Histone deacetylases (HDACs) are epigenetic modifiers that modulate …

B lymphocytes play a critical role in humoral immunity. Abnormal B cell development and
function cause a variety of hematological malignancies such as myeloma, B cell lymphoma …

Double-hit lymphoma (DHL) and double-expressor lymphoma (DEL) are aggressive forms
of lymphoma that require better treatments to improve patient outcomes. CKD-581 is a new …

DLBCL, the most common lymphoid malignancy in adults, is an aggressive form of non-
Hodgkin lymphoma (NHL) with significant heterogeneity in terms of gene expression …

Introduction: Histone acetylation alters DNA transcription and protein expression. Aberrant
acetylation is seen in tumor cells. Histone deacetylase inhibitors (HDACis) act by modifying …

Single histone deacetylases inhibitors (HDACis) or current combination therapies show
limited clinical efficiency in facing the striking heterogeneity of diffuse large B‐cell lymphoma …